Know Cancer

forgot password

Lung Cancer Immunotherapy With Vaccine 1650-G and Yeast Derived β-Glucan

Phase 1
21 Years
Not Enrolling
Lung Cancer

Thank you

Trial Information

Lung Cancer Immunotherapy With Vaccine 1650-G and Yeast Derived β-Glucan

Open-label pilot (Phase II) study to assess the immunologic activity of a cellular vaccine
composed of killed allogeneic tumor cells (1650-G) and GM-CSF in patients with stage I-IIIA
NSCLC after definitive therapy. (Surgery, Surgery plus Radiation Therapy, or Surgery,
Radiation Therapy plus Adjuvant Chemotherapy).

Inclusion Criteria:

- Histologically proven, surgically resected stage I-IIIA NSCLC (Bronchoalveolar
carcinomas are eligible).

- Must have read, voiced understanding of and signed an informed consent document.

- At least 21 years old

- At least 4 weeks but no more than 12 months post surgical resection.

- At least 4 weeks since completion of chemotherapy or radiation therapy (adjuvant)

- No evidence of disease following definitive initial therapy evidenced by a CXR, CT or
PET scan within 6 weeks of accrual.

- ECOG performance status of 0 to 2 (Section 19.1)

- Adequate organ and marrow function defined as follows:

- Hemoglobin ≥9.0 gm/dL

- Absolute neutrophil count (ANC) ≥1,500/mcl

- Platelet count ≥ 75,000/mcl

- AST <2.5 x upper limit of normal

- ALT <2.5 x upper limit of normal

- Creatinine Clearance (CCr) >50 ml/min

- Female patients must not be pregnant or breastfeeding. Women of childbearing
potential must have a negative pregnancy test and agree to use acceptable birth
control until the "analysis for immunologic response" 16 weeks after the second
vaccination. Study doctor will discuss acceptable methods of contraception with

Exclusion Criteria:

- Patients must not have not have no active residual or progressive lung cancer (Stable

- History of other malignancies unless they have had curative treatment completed
greater than (≥) five years prior to enrollment or one of the following;
appropriately managed Carcinoma in situ, basal cell carcinoma of the skin or
non-metastatic squamous cell carcinoma of the skin.

- Patients must not be chronically immunosuppressed.

- Patients with HIV and other immunosuppressive disorders and patient who chronically
use immunosuppressive medications are excluded. Patients should not be taking
immuno-suppressive steroids for at least 4 weeks prior to enrollment

- Individuals with conditions that might require shorter courses of immunosuppressive
oral medications (e.g. steroids) during the initial 16 weeks following immunization
are excluded.

- Patients should not have taken or plan to take other immunologically active agents
(eg flu vaccines) for a twelve week period, beginning 2 weeks prior to first dose of
beta-glucan and two weeks following last dose of beta glucan.

- Patients must not have a known history of infectious hepatitis.

- Because of the unknown effects of this treatment on the fetus pregnant females, and
childbearing females and males not willing to use contraception are not eligible.

- Patients must not have cardiovascular disease defined as:

- New York Heart Association Class III or IV congestive heart failure

- hemodynamically significant valvular heart disease

- myocardial infarction within the last six months

- active angina pectoris

- uncontrolled ventricular arrhythmias

- stroke within one year

- known cerebrovascular disease

- Patients may not have received any other investigational agents or participated in
any investigational drug study within 4 weeks preceding initiation of study

- No known allergies or history of allergic reactions to any colony stimulating factor

- No known intolerance to yeast derive β-glucan

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Immunologic response to vaccine

Outcome Description:

Increase in number of peripheral blood T cells recognizing cancer antigens

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Edward Hirschowitz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Kentucky


United States: Food and Drug Administration

Study ID:




Start Date:

October 2011

Completion Date:

February 2013

Related Keywords:

  • Lung Cancer
  • lung cancer
  • Lung Neoplasms



University of KentuckyLexington, Kentucky  40536-0098